Lenbelintide is named as an intervention in 6 current clinical trials in our USA, China, Canada, Japan, UK, India, Germany, Poland, South Korea, Taiwan, Australia, Brazil, Spain, Sweden, Denmark, Turkey, Israel, France, Italy and Czechia registers. 5 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is AstraZeneca. The most-studied condition is Obesity or Overweight. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Lenbelintide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus
2025-523295-23-00 · Nutritional and Metabolic Diseases
|
Phase 3 | Authorised | AstraZeneca AB | Sweden, Denmark |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 6 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
6 current trials in our USA, China, Canada, Japan, UK, India, Germany, Poland, South Korea, Taiwan, Australia, Brazil, Spain, Sweden, Denmark, Turkey, Israel, France, Italy and Czechia registers name Lenbelintide (also registered as AZD6234) as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 6 trials are recruiting: 5 with sites in USA, 3 with sites in China, 3 with sites in Canada, 3 with sites in Japan, 2 with sites in UK, 2 with sites in India, 2 with sites in Germany, 2 with sites in Poland, 2 with sites in South Korea, 2 with sites in Taiwan, 2 with sites in Australia, 2 with sites in Brazil, 1 with sites in Spain, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Turkey, 1 with sites in Israel, 1 with sites in France, 1 with sites in Italy and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is AstraZeneca. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lenbelintide works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lenbelintide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lenbelintide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.